** Shares of lab operator Quest Diagnostics DGX.N rise as much as 7% to an over three-year high of $166.39
** Co's Q4 adj EPS of $2.23 beats Wall Street estimates of $2.19 - data compiled by LSEG
** DGX's Q4 revenue of $2.62 bln is above estimates of $2.58 bln
** Co expects 2025 revenue between $10.70 and $10.85 bln, above estimates of $10.67 bln
** Shares of peer Labcorp LH.N up 4.8%
** DGX shares rose 9.4% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。